GB1576216A - 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them - Google Patents
2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them Download PDFInfo
- Publication number
- GB1576216A GB1576216A GB5400076A GB5400076A GB1576216A GB 1576216 A GB1576216 A GB 1576216A GB 5400076 A GB5400076 A GB 5400076A GB 5400076 A GB5400076 A GB 5400076A GB 1576216 A GB1576216 A GB 1576216A
- Authority
- GB
- United Kingdom
- Prior art keywords
- morpholine
- indenyloxymethyl
- mixture
- acid addition
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical class C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 26
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 18
- NWINIMXDTPZGDL-UHFFFAOYSA-N 2-(1h-inden-4-yloxymethyl)morpholine Chemical compound C=1C=CC=2CC=CC=2C=1OCC1CNCCO1 NWINIMXDTPZGDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- KESZKNDYDVWXGW-UHFFFAOYSA-N 2-(1h-inden-4-yloxymethyl)oxirane Chemical compound C=1C=CC=2CC=CC=2C=1OCC1CO1 KESZKNDYDVWXGW-UHFFFAOYSA-N 0.000 claims description 6
- AXHFKRWTQUZIAL-UHFFFAOYSA-N 2-(3h-inden-4-yloxymethyl)oxirane Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CO1 AXHFKRWTQUZIAL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- NGDZDTDIMQNKOP-UHFFFAOYSA-N 4-(3h-inden-4-yloxymethyl)morpholine Chemical compound C=1C=CC=2C=CCC=2C=1OCN1CCOCC1 NGDZDTDIMQNKOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000047 product Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 238000000921 elemental analysis Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 229940113083 morpholine Drugs 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- -1 7-indenyloxymethyl Chemical group 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- RHJCDXFCUVOILU-UHFFFAOYSA-N 2-(1h-inden-4-yloxymethyl)morpholine;hydrochloride Chemical compound Cl.C=1C=CC=2CC=CC=2C=1OCC1CNCCO1 RHJCDXFCUVOILU-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 229960001252 methamphetamine Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001255 viloxazine Drugs 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- APJFAKMCPZRILI-UHFFFAOYSA-N 1-(2-hydroxyethylamino)-3-(3h-inden-4-yloxy)propan-2-ol Chemical compound OCCNCC(O)COC1=CC=CC2=C1CC=C2 APJFAKMCPZRILI-UHFFFAOYSA-N 0.000 description 1
- MMLSVAZDIYUZKQ-UHFFFAOYSA-N 2-(1h-inden-1-yloxymethyl)morpholine Chemical compound C1=CC2=CC=CC=C2C1OCC1CNCCO1 MMLSVAZDIYUZKQ-UHFFFAOYSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 1
- ONRREFWJTRBDRA-UHFFFAOYSA-N 2-chloroethanamine;hydron;chloride Chemical compound [Cl-].[NH3+]CCCl ONRREFWJTRBDRA-UHFFFAOYSA-N 0.000 description 1
- LKSJUXIZTGZHNQ-UHFFFAOYSA-N 4-(morpholin-2-ylmethoxy)-2,3-dihydro-1h-inden-1-ol Chemical compound OC1CCC2=C1C=CC=C2OCC1CNCCO1 LKSJUXIZTGZHNQ-UHFFFAOYSA-N 0.000 description 1
- AYWVCFPWJCQEEH-UHFFFAOYSA-N 4-[(4-tritylmorpholin-2-yl)methoxy]-2,3-dihydro-1h-inden-1-ol Chemical compound OC1CCC2=C1C=CC=C2OCC(OCC1)CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 AYWVCFPWJCQEEH-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GPPMCRWIIPGDNI-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.C1C=CC2=C(C=CC=C12)OCC1CNCCO1 Chemical compound C(C=C/C(=O)O)(=O)O.C1C=CC2=C(C=CC=C12)OCC1CNCCO1 GPPMCRWIIPGDNI-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241001262617 Japonica Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000000891 anti-reserpine Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- WSYUEVRAMDSJKL-UHFFFAOYSA-N ethanolamine-o-sulfate Chemical compound NCCOS(O)(=O)=O WSYUEVRAMDSJKL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000005583 trifluoroacetylation reaction Methods 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(54) 2-(7-INDENYLOXYMETHYL)-MORPHOLINE DERIVATIVES AND PROCESS OF PRODUCING THEM
(71) We, YAMANOUCHI PHAR
MACEUTICAL CO. LTD., a Company organised and existing under the laws of
Japan, of No. 5-1, Nihonbashi-Honcho 2chome, Chuo-ku, Tokyo, Japan, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: This invention relates to an improvement in or modification of the invention of British
Patent Application No. 1762/76 (1,535,276) (hereinafter referred to as the main invenrion).
According to the main invention, there is provided a compound represented by the formula
wherein R' and R3 each represents a hydrogen atom, a lower alkyl group, or a phenyl group;
R2 represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, a phenyl group, or a benzyl group; and one of the dotted lines represents a single bond and the other represents a double bond; and the acid salts thereof.
The main invention also includes a process of producing these compounds, a process of preparing formulations containing these compounds, and is further concerned with the uses of these compounds.
The present invention is based on the discovery that one compound included in the scope of the main invention, but not disclosed practically in the specification thereof (so far as concerns its particular physical and chemical properties) is particularly useful as an antidepressant agent. It is also based on the discovery of a novel process of producing such compound, which process is not described in the specification of the main invention.
Anti-depressant agents having a morpholine ring are already known as disclosed in, for example,-British Patent No. 1,138,405 and
British Patent No. 1,260,886.
The compound which is believed to have the best activity among the compounds disclosed in these patent specifications is 2-(2-ethoxy- phenoxymethyl)morpholine, which is usually known as Viloxazine (see "Nature", 238, 157-158 (1972)). A series of studies made by K. B. Mallion, A. H. Todd, R. W. Turner, et al (the inventors of Viloxazine) suggests a relationship between the chemical structures and pharmacological activities of the known compounds. That is, it is preferred that the compound has one substituent at the 2-position of a phenoxy group bonded to morpholine.
Furthermore, when the phenoxy group forms a fused ring, it is preferred that, for example, a tetralin-type ring is formed by the notional condensation with a tetramethylene group.
Against this, when the condensed ring forms an indane-type ring by the condensation with a trimethylene group, the pharmacological effect becomes less.
According to this invention there is provided an acid addition salt of 2-(7-indenyloxymethyl)morpholine represented by the general formula
In the spedfication of the main invention, the compound obtained in Example 10 is described as 2-(4- or 7-indenyloxymethyl) morpholine, having a maleate with a melting point of 135--137"C. As the result of further investigations, the present inventors have dfs- covered that the compound obtained in
Example 10 is, in fact, a mixture of 2-(7indenyloxymethyl ) morpholine (hereinafter, referred to as the 7-isomer), and 2-(4-indenyl oxymethyl)morpholine (hereinafter, referred to as the 4-isomer) similar to the compound obtained in Example 16 of the specification of the main invention. Furthermore, the inventors have further succeeded in separating the product into 2-(7-indenyloxymethyl)moipholine maleate melting at 154-1560C and 2 - (4 - indenyloxymethyl)morpholine maleate melting at 167--1690C. This separation and the resultant compounds are not practically disclosed in the specification of the main invention. It has further been experimentally found that the 2- (7-indenyloxy- methyl)morpholine acid addition salts obtained have better pharmacological effects compared with the 4-isomer and hence should be favoured for use as medicamenti.
The inventors have further succeeded in discovering a novel process of producing the desired product different from the processes described in the specification of the main invention, and also an isomerisation process for producing the desired product.
That is, 1,2-epoxy-3-(7-indenyloxy)propane and/or 1,2 - epoxy - 3 - (4 - indenyloxy)propane represented by the formula II
wherein one of the dotted lines represents a single bond and the other represents a double bond, is reacted with an amine represented by the general formula III HNH2-CH,-Z III wherein Z represents a halogen atom or -OSO,R4 (wherein R4 represents a hydrogen atom, an aryl group, or a lower alkyl group) in the presence of a base to produce a mixture of 2 - (7 - indenyloxymethyl)morpholine and 2 - (4 - indenyloxymethyl)morpholine, shown by the general formula IV
wherein the dotted lines have the same meaning as above, and to the mixture obtained is added an acid in an amount less, and preferably only slightly less, than the stoichiometric amount required to isomerise 2z(4-indenyloxy- methyl)morpholine whereby the acid addition salt of 2 - (7 - indenyloxymethyl)morpholine shown by the general formula I
is obtained.
Now, the lower alkyl group shown by R4 in the compounds represented by general formula III is a straight or branched chain alkyl group having up to 6 carbon atoms. Practical examples of the alkyl group are a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl, hexyl or isohexyl group. Examples of the halogen Z of the compound of general formula III are chlorine, bromine, or iodine.
The aryl group shown by R4 in the compound includes a phenyl and p-tolyl group.
The 2 - (indenyloxymethyl)morpholine
(a mixture of 7-isomer and 4-isomer) shown by general formula IV is usually obtained by reacting 1,2 - epoxy - 3 - (7 - indenyloxy)propane and/or 1,2 - epoxy - 3 - (4indenyloxy)propane with the amine represented by formula III in a solvent such as one or more of water, methanol, ethanol, isopropanol, n-butanol,. tert-butanol, ethylene glycol, tetrahydrofuran or dioxane, in the presence of an alkali metallhydroxide such as sodium hydroxide or potassium hydroxide or an alkaline earth metal hydroxide such as barium hydroxide, or calcium hydroxide at room or higher temperatures. The product then obtained is a mixture of the 7-isomer and 4-isomer as described above since the product obtained equilibrates by tautomerism under the prevailing basic conditions.
The mixture of the acid addition salt of the 7-isomer and the acid addition salt of the 4isomer as obtained by adding an acid to the mixture prepared above has the unexpected property that the 4-isomer is isomerised into the 7-isomer by the presence of a small amount less than the stoichiometric amount of a base and only the acid addition salt of the 7-isomer is actually obtained, due to isomerisation within the mixture of the two isomers (free bases) obtained by the reaction. Such isomerisation can be effected on the reaction product mixture as it is, or after purification by adding thereto in an organic solvent an acid in an amount slightly less than the stoichiometric amount required to react therewith, the remaining free base itself then acting as the base, or by adding to the mixture of the isomers an acid in a stoichiometric amount or an amount slightly m excess of the stoicio- metric amount, to convert the whole isomeric mixture into acid addition salt and then adding a small amount of a basic material to the salt in an organic solvent. In the isomerisation reaction, it is unnecessary to dissolve the tautomeric mixture (free bases, acid addition salts) in a solvent. Purification of the mixture of the isomers can be performed by conventional methods such as, for example, filtration, concentration, extraction, distillation, column chromatography or recrystallisation.
Examples of the acid used for forming the acid addition salts of the isomers are, by way of illustration, organic acids such as citric, acetic, lactic, maleic, fumaric, benzoic, tartaric, ascorbic, succinic or malic acid, and inorganic acids such as hydrochloric, sulfuric, phosphoric or nitric acid. Illustrative examples of the basic materials used for the isomerisation are a free tautomeric mixture, and other organic and inorganic bases such as pyridine, triethylamine, sodium hydroxide or barium hydroxide.
Furthermore, after converting the aforesaid mixture of isomers into the mixture of the acid addition salts of the isomers by addition to the isomer mixture as it is or after purification of a stoichiometric or slightly excess amount of an acid then the acid addition salt of the 7isomer and the acid addition salt of the 4isomer can be separated and recovered by fractional recrystallisation. For the fractional recrystallisation, an organic solvent such as methanol and isopropanol is typically used.
The compound of this invention shows methamphetamine stereotyed increasing activity, which is one of the desired pharmacological properties for an antidepression agent, and further the observed activity is stronger than that of the known antidepressant agent,
Amitriptyline.
The compound of this invention also has shown a stronger antireserpine activity than that of known compounds, which activity is one of the desired pharmacological properties for an antidepressant agent.
The acute toxicity of the compound of this invention upon oral administration is observed to be about 9 of the known compounds, and compound of this invention exhibit an excellent safety coefficient for medical treatment, considering the potential activities of the compound.
The compound of this invention further shows higher activity in potentiation of the effect of 5-hydroxytryptophan (which is one of the desirable effects for an antidepressant agent) compared with the known compounds Amitriptyrine and Imipramine.
Furthermore, rhe isolated 7-isomer acid addition salt shows better pharmacological activity than the 4-isomer acid addition salt.
The present invention therefore further provides a pharmaceutical composition comprising the novel compound together with pharmaceutically acceptable diluent.
The aforementioned activities of compound of the present invention are demonstrated by the following experiments: EXPERIMENT 1.
The effects of the compounds on methamphetamine-induced stereotyped behaviour in rats (male Wistar strain, age 8 weeks) were examined according to the method of Ueki el al. (Folia Pharmacologica Japonica, 68, 716
1972).
The rats were placed in separate plastics cages for 1 hour to be accustomed to the experimental conditions and then the compounds under test were given intraperitoneally followed by an intraperitoneal application after 1 hour of methamphetamine (5 mg/Kg). The influence of the compounds on the agitated behaviour of the rate was observed every 30 minutes till 5 hours thereafter.
The EDso of the compounds under test were 5.0 mg/Kg and 12.5 mg/lKg i.p. for 2 - (7 - indenyloxymethyl)morpholine hydrochloride and 2 - (4 - indenyloxymethyl)morpholine hydrochloride, respectively. The former was 2.5 times as potent as the latter.
EXPERIMENT 2.
The effects of the compounds on reserpineinduced hypothermia in mice (male ICR-JCL strain, age 5 weeks) was investigated by the method of Ueki et al. (ibid).
The mice were pretreated with reserpine (3 mgjKg s.c.) and housed in separate plastics cages for 17 hours. The room temperature was kept at 23 10 C. The compounds under test were given orally and the rectal temperature of the mice was measured 5 hours thereafter.
The differences of the rectal temperature (AT) in the rats compared to those of a control group, and the sum of the differences (OT), were calculated. Thereafter by graphical estimation of
ED T= 1.50C, the ED T=!1.50C of 2 - (7 - indenyloxymethyl)morpholine hydrochloride and 2 - (4 - indenyloxymethyl)morpholine hydrochloride were 1.8 mg/Kg and 2.4 mg/Kg p.o., respectively. The former proved to be more potent than the latter in efficacy.
The following examples illustrate the present invention. The starting materials used in Examples 5 and 6 may be prepared by methods as described in the specification of the main invention.
Reference Example l(a).
In a mixed solution of 29 ml. of 70% sodium hydroxide solution and 35 g. of 2aminoethyl hydrogen sulfate (H2N CH2CH2OSO3H) was added 9.4 g. of 1-(7-indenyloxy)-2,3epoxypropane (containing about 35% 1-(4indenyloxy) - 2,3 - epoxypropane) dissolved in 50 ml. of methanol and the mixture was stirred for one hour at 55 lC. To the mixture was added 50 ml. of 70% sodium hydroxide and stirred for further 16 hours at 55"C. After cooling, 300 ml. of water was added to the reaction mixture and then the product was extracted thrice each with 100 ml. of toluene.
The extracts were combined, washed with water, dried, and then the residue was distilled. By collecting the fractions having boiling points of 146156,C./0.5 mm Hg, 6.7 g (yield 58.0%) of oily 2-(7-indenyloxymethyl)morpholine (containing 32% 2 (4 - indenyloxymethyl)morpholine) was obtained.
The proportions of the both isomers was measured by gas chromatography after trifluoroacetylation the isomer mixture with trifluoroacetic anhydride.
Elemental analysis for C14H1,NO2: C(%) H(%) N(%)
Calculated: 72.70 7.411 6.06
Found: 72.91 7.50 5.95
Reference Example 1'(b).
In 30 ml. of acetone was dissolved 3 g. of the oily base obtained from Reference
Example l(a), and after acidifying the solution thus obtained with isopropanol-hydrochloric acid, the solution was mixed with 50 ml. of ether. The mixture was allowed to stand overnight in an ice chamber at - 100C.
to precipitate crystals, which were recovered by filtration to provide 2.8 g. (yield 80.4%) of 2 - (7 - indenyloxymethyl)morpholine hydrochloride (containing 40% 2 - (4- indenyloxymethyl )morpholine hydrochloride) melting at 143-1550C.
The proportions of the both isomers in the product was measured by gas chromatography after trifluoroacetylating the product with trifluoroacetic anhydride.
Elemental analysis for Cl4Hl8NO2Cl: C(%) Hl(%) N(%) C1(%) Calculated: 62.80 6.78 5.23 13.24
Found: 62.84 6.81 5.24 13.01
Example 1.
In 70 ml. of acetone was dissolved 3 g. of the oily base obtained from Reference Example 1(a), the solution was weakly acidified by isopropanol-hydrochloric acid under ice-cooling and then allowed to stand overnight in a refrigerator. The crystals thus precipitated were recovered by filtration and washed with acetone and then ether to provide 1.1 g. of 2 - (4 - indenyloxymethyl)morpholine hydrochloride (containing 15% 2-(7-indenyloxymethyl)morpholine hydrochloride) showing melting point of 159-1630C. Then, by repeating the recrystallization from methanol, pure 2 - (4 - indenyloxymethyl)morpholine hydrochloride showing melting point of 175-1760C. was obtained.
Elemental analysis for :C14H1sNO,Cl N(%) Calculated: 5.23
Found: 531 Nuclear magnetic resonance spectra: (CDC13+lD6DMSO; ppm) 3.0-3.4 (4H, m,
4.0-4.1 (4H, m O~CH2,
4.3 (1H, m,
3.4 (2H,
6.5 (1H, doublet, J =6Hz)
7.0 (1H, doublet, J = 6 Hz)
6.8 (1H, q,
7.1 (2H, d,
The mother liquor and washings were combined, dried up under reduced pressure, and after adding thereto 50 ml. of toluene followed by drying again under reduced pressure, the residue obtained was dissolved once in 30 ml.
of acetone. The solution thus obtained was allowed to stand overnight at room temperature and the crystals thus formed were recovered by filtration and washed with acetone to provide 1.7 g. of 2z(7-indenyloxymethyl)- morpholine hydrochloride (containing 10% 4indenyloxy isomer) showing a melting point of 138-153 C. The proportions of the both isomers was measured by gas chromatography after trifluoroacetylating the product with trifluoroacetic anhydride. Then, by repeating the recrystallization from methanol, 1.7 g.
of pure 2 - (7 - indenyloxymethyl)morpholine hydrochloride having the following properties was obtained.
Elemental analysis for C14H18NO2Cl: N( / ) Calculated: 5.23 Found: 5.29 Nuclear magnetic resonance spectra: (CDCl,+D6-DMSO: ppm): 3.0-3.4 (4H, m,
4.04.2 (4H, m -02
4.3 (1H, m,
3.34 (2H,
6.58 (1H, doublet,
J=6 Hz) 6.84 (llH, doublet
J=6 Hz) 6.78 (H, d,
7.04 (1H, d,
7.20 (1H, t,
10.0 (2H,
Reference Example 2.
A mixture of 4.7 g. of a mixture of 1-(4- indenyloxy) - 2,3 - epoxypropane and 1
(7 - indenyloxy) - 2,3 - epoxypropane, 1-1.5 g.
of 2-chloroethylamine hydrochloride, 10 g. of sodium hydroxide, 100 ml. of ethanol, and 50 ml. of water was stirred for 24 hours at 60--650C. After cooling, the mixture was acidified by 5% hydrochloric acid and ethanol was distilled away under reduced pressure.
The resulted aqueous solution was washed with ethyl acetate, alkalified with an aqueous 5% sodium hydroxide solution, and then extracted thrice each with 50 ml. of ether. The extracts were combined and dried over anhydrous sodium sulfate and then ether was distilled away from the extract under reduced pressure. The oily material obtained was subjected to a silica gel chromatography and eluted by a solvent mixture of chloroform:methanol l(9:l) and from the eluate 500 mg. of a mixture of 2-(4-indenyloxymethy1)- morpholine and 2 - (7 - indenyloxymethyl)morpholine (the proportions of 7-indenyl isQmer:4-indenyl isomer was 17:8) was obtained.
The product obtained coincided completely with the product obtained in Reference
Example ll(a).
Reference Example 3.
Into 10.6 ml. of pyridine was added 2.5 g.
of chlorosulfonic acid with stirring at 05 C and then 5.0 g. of a mixture of 14(4-indenyl- oxy) - 3 - , - hydroxyethylamino - 2- propanol and 1 - (7 - indenyloxy) - 3 hydroxyethylamino - 2 - propanol dissolved
in 10 ml. of pyridine was added dropwise
to the mixture. The reaction mixture was
stirred for 3 hours at 250C. and then the
solvent was distilled away under reduced pres
sure. The oily material obtained was added to a solution consisting of 2.4 g. of sodium hydroxide, 13 ml. of water, and 26.4 ml. of ethanol and refluxed for 24 hours.
After cooling the reaction mixture, ethanol was distilled away under reduced pressure,
50 ml. of water was added to the residue, and the mixture was extracted thrice each with 50 ml. of ether. The extracts were combined, dried over anhydrous sodium sulfate, and then ether was distilled away under reduced pressure. The residue formed was subjected to silica gel column chromatography and eluted by a solution mixture of chloroform and methanol (9:1). From the eluate, 1.1 g. of a mixture of 2 (4-indenyloxym.ethyl)- morpholine and 2 - (7 - indenyloymethyl)- morpholine (the proportions of the 7-indenyl compound and the 4-indenyl compound was 17:8) was obtained. The product obtained coincided completely with that of obtained in
Reference Example 1(a).
Example 2.
In 20 ml. of acetone was suspended 10 g.
of a mixture (3:7) of 2-(4-indenyloxymethyl)- morpholine hydrochloride and 2 - (7indenyloxymethyl) morpholine hydrochloride and after adding to the suspension 3 g. of a mixture (3:7) of 2 - (4 - indenyloxy- methyl)morpholine and 2 - (7 - indenyl- oxymethyl)morpholine, the resultant mixture was stirred for 24 hours at room temperature. The crystals thus precipitated were recovered by filtration, thoroughly washed with acetone, and 10 g. of the crude crystals recovered were recrystallized from 40 ml. of methanol to provide 7.0 g. of 2-(7-indenyl- oxymethyl)morpholine hydrochloride.
Elemental analysis for C14H18O2NCl: C(%) H(%) N(%) Cl(%) Calculated: 62.80 6.78 5.23 13.24
Found: 63.01 6.75 5.11 )12.98 Nuclear magnetic resonance spectra (cDCl8+D6-DMSO): 8 (ppm):
3.0-3.4 (m, 4H,
4.0-4.2 (m, 4H, wCE2
4.3 (m, lH,
3.34 (2H,
6.58 (doublet, 1H,
J=6 Hz) 6.84 (doublet, 1H, JI 6 Hz)
6.78 (d, 1H;
7.04 (d, 1H,
7.20 (t, 1H,
Example 3.
In 20 runt. of jsopropyl alcohol was dissolved a mixture of 10 g. (0.043 mol) (3:7) of 2 (4 - indenyXoxyrn thyl)morpholine and 2 (7 - indenyIoxymetfyl)morpholine and after adding to the solution 5.9 ml. (0.032 mol) of 20% w/v hydrogen chloride in isopropyl alcohol, the rnixture was, stirred for 24 hours at room temperature. The crystals thus precipitated were recovered by filtration, thoroughly washed with acetone, an,d then recrystallized from 40 ml of methanol to provide 7.7 g. of 2-(7-indenyloxymethyl)mor- pholine hydrochloride.
Elemental analysis for C14H18O2NCl:
C(%) H(%) N(%) Cl(%)
Calculated: 62.80 6.78 5.23 13.24
Found: 62.54 6.63 5.08 13.00
Example 4.
In 20 ml. of methanol was suspended 10 g.
Of a mixture (3:7) of 2-(4-lndeny, oxymethyl) morpholine hydrochloride and 2 - (7indenyloxymethyl ) morpholine hydrochloride and after adding to the suspension 0.3 g. of triethylamine, the mixture was stirred for 24 hours at room temperature. The crystals thus precipitated were recovered by filtration, thoroughly washed with acetone, and recrystallized from 40 ml. of methanol to provide 6.3 g. of 2 - (7 - indenyloxymethyl)morpholine hydrochloride.
Elemental analysis for C14H18O2NCl: O(%) H(%) N(%) Cl(%) Calculated: 62.80 6.78 5.23 13.24
Found: 62.77 6.83 5.40 13.29
Example 5.
In 500 ml. of ethanolic hydrochloric acid (350 ml. of 0.5 N hydrochloric acid and 150 ml. of ethanol) was dissolved 5.0 g. of 4-triphenylmethyl - 2 - (1 - hydroxy - 4 - indanyloxymethyl)morpholine and the solution was refluxed 17 hours. After cooling the reaction mixture, ethanol was distilled away under reduced pressure until the whole volume of the reaction mixture became about 350 ml:
Sodium chloride was added to the reaction
mixture to cause salting out and the mixture was extracted thrice each with 200 ml. of chloroform. The chloroform extracts were combined, dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. Then, by adding acetone to the syrupy residue formed, 2.0 g.
of 2 - (7 - indenyloxyrnethylBmorpholine hydrochloride was obtained as precipitates.
Melting point of the hydrochloride:
155-156 C.
Melting point of the maleate: 154-156 C.
Elemental analysis for C14H18NO2Cl: C(%) H(%) N(%) Cl(%) Calculated: 62.75 6.78 5.23 13.24
Found: 62.81 6.79 5.40 13.11
Nuclear magnetic resonance spectra
CDCl3+D6-DMSO): 8 (ppm) 3.0-3.4 (m, 4H,
4.04.2 (m, 411,
4.3 (m, 1H,
3.34 (2H,
6.58 (doublet, 1.H
J=6Hz) 6.84 (doublet, 1R
J=6 Hz) 6.78 (d, 1H,
7.04 (d, H,
7.20 (t, 1H,
10.0
Example 6.
To 1.0 g. of 2-(1-hydroxy-4-indanyloxy- methyl)morpholine were added 50 ml. of ethanol and 50 ml. of 0.5 N hydrochloric acid and the mixture was re
fluxed for 17 hours. After cooling, the
reaction mixture was concentrated under re
duced pressure until the whole volume became
about 50 ml and then sodium chloride was
added thereto to cause salting out. The reaction mixture was extracted thrice each with 50 ml. of chloroform. The extracts were combined, dried over anhydrous magnesium sul
fate, and the solvent was distilled away. The syrupy residue formed was dissolved in a - small amount of isopropyl alcohol and then acetone was added to the solution to provide 830 mg. of light yellow powder of 2-(7 indenyloxymethyl ) morpholine hydrochloride as the precipitates.
By recrystallizing the product from acetone,
the colorless acicular crystals of the aimed
compound having melting point of 155-156 C were obtained.
Elemental analysis for C14H18NO2Cl: C(%) H(%) N(%) C1!(%) Calculated: 62.75 6.78 5.23 1324
Found: 63.43 6.72 5.43 12.91
Nuclear magnetic resonance spectra
(CDCl8+D6-DMSO) 3 (ppm):
3.0-3.4 (m, 4H
4.0-42 (m, 4H,
4.3 (m, 1H,
3.34 (2H,
6.58 (doublet, 1H
J=6Hz) 6.84 (doublet, 1H,
J=6Hz) 6.78 (d, 1,
7.04 (d, 1H
7.20 (t, 1H,
10.0
WHAT WE CLAIM 'IS:- 1. IAn acid addition salt of 2 < (7-indenyloxy- methyl)morpholine represented by the general formula
2. A process for producing an acid addition salt of 2 - (7 - indenyloxymethyl)morpholine according to claim 1 which comprises reacting at least one of 1,2 - epoxy - 3 - (7indenyloxy)propane and 1,2 - epoxy - 3 (4 - indenyloxy)propane, represented by the general formula
wherein one of the dotted lines represents a single bond and the other represents a double bond, with an amine represented by the general formula H2'N-CH2CH2Z wherein Z represents a halogen atom or -OSO,R4 (wherein R4 represents a hydrogen atom, an aryl group or a lower alkyl group) in the presence of base to f
Claims (1)
- **WARNING** start of CLMS field may overlap end of DESC **.6.78 (d, 1,7.04 (d, 1H7.20 (t, 1H,10.0WHAT WE CLAIM 'IS:-1. IAn acid addition salt of 2 < (7-indenyloxy- methyl)morpholine represented by the general formula2. A process for producing an acid addition salt of 2 - (7 - indenyloxymethyl)morpholine according to claim 1 which comprises reacting at least one of 1,2 - epoxy - 3 - (7indenyloxy)propane and 1,2 - epoxy - 3 (4 - indenyloxy)propane, represented by the general formulawherein one of the dotted lines represents a single bond and the other represents a double bond, with an amine represented by the general formula H2'N-CH2CH2Z wherein Z represents a halogen atom or -OSO,R4 (wherein R4 represents a hydrogen atom, an aryl group or a lower alkyl group) in the presence of base to form a mixture of the 2 - (7 - indenyloxymethyl)morpholine and the 2 - (4 - indenyloxymethyl)morpholine, represented by the general formulawherein the dotted lines have the same significance as defined above, and adding to the mixture an acid in an amount less than the stoichiometric amount to isomerise the 2-(4indenyloxymethyl ) morpholine.3. tA process for producing an acid addition salt of 2 - (7 - indenyloxymethyl)morpholine according to claim 1 which comprises adding to a mixture of the 2-i(7-indenyloxymethyl)morpholine and the 2 - (4 indenyloxymethyl) morpholine, represented by the general formulawherein one of the dotted lines represents a single bond and the other represents a double bond, an acid in an amount less than the stoichiometric amount to isomerise the 2-(4indenyloxymethyl )morpholine.4. A process for producing an acid addition salt of a 2~l(7-indenyloxymethyl)morpholine according to claim 1 which comprises adding to a mixture of the acid addition salts of the 2 - (7 - indenyloxymethyl)morpholine and the 2 - (4 - indenyloxymethyl)morpholine, represented by the general formulawherein one of the dotted lines represents single bond and the other represents double bond, less than the stoichiometric amount of base to isomerise the 2-(4-indenyloxymethyl)morpholine.5. A process for preparing an acid addition salt of 2 - (7 - indenyloxymethyl) morpholine, substantially as described in any one of the Examples.6. An acid addition salt of 2-(7-indenyloxy- methyl)morpholine when prepared by a process according to any one of claims 2 to 5.7. A pharmaceutical composition comprising an acid addition salt of a 2-(7-indenyloxymethyl)morpholine according to claim 1 or claim 6 together with a pharmaceutically acceptable diluent.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50012177A JPS5188972A (en) | 1975-01-29 | 1975-01-29 | 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho |
| JP15564775A JPS5278883A (en) | 1975-12-25 | 1975-12-25 | Synthesis of novel indene derivatives |
| JP3545076A JPS6025430B2 (en) | 1976-03-31 | 1976-03-31 | Method for producing novel morpholine derivatives |
| JP12896276A JPS6039671B2 (en) | 1976-10-27 | 1976-10-27 | Method for producing acid addition salt of 2-(7-indenyloxymethyl)morpholine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1576216A true GB1576216A (en) | 1980-10-01 |
Family
ID=27455749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB5400076A Expired GB1576216A (en) | 1975-01-29 | 1976-12-24 | 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE2707678A1 (en) |
| GB (1) | GB1576216A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123496C1 (en) * | 1993-02-10 | 1998-12-20 | Яманоути Фармасьютикал Ко., Лтд. | Morpholine derivative or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
-
1976
- 1976-12-24 GB GB5400076A patent/GB1576216A/en not_active Expired
-
1977
- 1977-02-23 DE DE19772707678 patent/DE2707678A1/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123496C1 (en) * | 1993-02-10 | 1998-12-20 | Яманоути Фармасьютикал Ко., Лтд. | Morpholine derivative or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2707678A1 (en) | 1977-10-13 |
| DE2707678C2 (en) | 1987-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU638413B2 (en) | Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance | |
| CH375017A (en) | Process for the preparation of novel imidazole derivatives | |
| CH646969A5 (en) | NOR-TROPANE BETA-AMINO-3 DERIVATIVES. | |
| JPH0794420B2 (en) | Process for producing substituted phenoxyacetaldehyde oximes | |
| JPH04264078A (en) | Preparation of piperazine derivative | |
| HU228204B1 (en) | New process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and use thereof for the synthesis of tianeptine | |
| CN106365966A (en) | Preparation method of benzyl aryl ether | |
| US4109088A (en) | 2-(indenyloxymethyl) morpholine derivatives | |
| PL175707B1 (en) | Novel 1-aryloxy-3-alkylamine 2-propanol esters and pharmaceutical agent | |
| HU182636B (en) | Process for producing pyrazolo-imidazol derivatives | |
| US3141019A (en) | Chaohj | |
| GB1576216A (en) | 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them | |
| HU216444B (en) | Process for preparation of phenylacetic acid derivatives | |
| US2574505A (en) | Process of preparing 2, 2-diphenyl-3-methyl-4-dimethylamino butyronitrile | |
| IE54599B1 (en) | 2-amino-1-(1,3-dioxolan-4yl)-ethanol compounds, their preparation and use | |
| US3435047A (en) | Process for preparing 3-aminoisoxazole derivatives | |
| CA1103247A (en) | Process for the preparation of acid addition salt of 2-(7-indenyloxymethyl)morpholine derivative | |
| PL139768B1 (en) | Method of obtaining novel derivatives of 8-aminoacylamino-4-aryl-2-methyl-1,2,3,4-tetrahydroisoquinoline | |
| HU201524B (en) | Process for producing polyhydrobenz(c,d)indolesulfonamides and pharmaceutical compositions comprising such compounds as active ingredient | |
| US11572333B2 (en) | Processes for the production of isomerically pure or enriched cis-clomiphene | |
| CA1086732A (en) | Process for the preparation of acid addition salt of 2-(7-indenyloxymethyl) morpholine derivative | |
| HU193454B (en) | Process for producing 3-phenyl-butyraldehyde derivatives | |
| KR800001699B1 (en) | Process for the preparation of amino-phenyl-ethanol amine | |
| DK153839B (en) | METHOD FOR PREPARING 5 - ((1-HYDROXY-1-METHYL) -ETHYL) -1-METHYL-2-NITROIMIDAZOLE | |
| JPS61118372A (en) | Novel pyrimidine derivative and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19950116 |